First Trust中小型成長強度ETF FSGS 深 滬
等待開盤 04-22 09:30:00 美东时间
31.0709
-0.266
-0.85%
華盛通- 最 高31.481
- 今 開31.481
- 成交量 727股
- 最 低 31.0709
- 昨 收 31.3373
- 總市值 2951.74万
- 52周最高 32.0754
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 28.04
- 委 比 0.00%
- 總股本 95.00万
- 歷史最高 32.5669
- 量 比 0.19
- 振 幅 1.31%
- 歷史最低 9.9631
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reported Earlier, Travere Therapeutics Wins FDA Approval Of FILSPARI For Focal Segmental Glomerulosclerosis Without Nephrotic Syndrome, Delivering 48% Proteinuria Reduction Vs 27% For Irbesartan In Phase 3 DUPLEX Study
FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndromeAdditional indication for FILSPARI expands total addressable population to more than
04-14 14:19
Maze Therapeutics' MZE829 Delivers First Clinical Proof-Of-Concept In APOL1-Mediated Kidney Disease With 61.8% Mean uACR Reduction In FSGS Subgroup
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated –– The
03-25 19:09
Asia Fuel Oil-HSFO retains downside risk in ample supply
Asia Fuel Oil-HSFO retains downside risk in ample supply SINGAPORE, Feb 25 (Reuters) - Asia's high sulphur fuel oil (HSFO) market steadied on Wednesday after a recent pare-back, though downside risk still lingered amid expectations of ample supply. The prompt March-April timespread for 380-cst HSFO
02-25 18:11
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study...
02-11 00:30
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
Asia Fuel Oil-Spot differentials steady, HSFO cracks firm on volatile crude
SINGAPORE, Dec 17 (Reuters) - Spot differentials for the Asia fuel oil market were little changed on Wednesday, though high-sulphur fuel cracks inched higher amid volatile crude prices. Benchmarks for...
2025-12-17 18:30
BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline
Dec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINE AKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTE...
2025-12-01 21:21
Travere Therapeutics highlights advancements in rare kidney and metabolic disease therapies in new corporate overview
Travere Therapeutics Inc. has published a corporate presentation outlining its latest strategic priorities and milestones for 2025. The company highlighted its focus on rare kidney and metabolic disea...
2025-11-01 09:06
BUZZ-Needham ups Amicus Therapeutics to 'buy'
** Needham upgraded Amicus Therapeutics FOLD.O to "buy" from "hold", seeing company's current valuation as an attractive entry point ** Brokerage sees lower regulatory risk for DMX-200 after an FDA de...
2025-09-18 21:17
BRIEF-Travere Therapeutics Provides Update On FDA Advisory Committee Meeting For FILSPARI In FSGS
Sept 10 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING FOR FILSPARI® (SPARSENTAN) IN FSGS TRAVERE THERAPEUTICS INC - FDA NO LONGER ...
2025-09-10 19:55
